TCG Crossover Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001839948

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 56 positions · Total reported value $3.54B · Top-10 concentration 53.3% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 44.3% · 7 new · 15 cut · 5 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.6% · vs SPY -9.8% · Prev Value $4.16B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.0% · Latest Value $3.54B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, TCG Crossover Management, LLC disclosed 56 equity positions with a combined reported value of $3.54B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 53.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were ABVX ($362.71M), CGON ($260.18M), AMLX ($181.69M). By sector, the heaviest allocations are Health Care 99.8%, Financials 0.1%.

Versus the prior quarter, TCG Crossover Management, LLC opened 7 new positions, trimmed 15 and fully exited 5, a turnover rate of 44.3% of positions. The portfolio's overlap with the prior quarter was 80% of names.

The largest new positions opened in Q3 2026 were ANIX ($145.59M), VNDA ($82.08M), ENTX ($35.66M).

Of the 5 positions fully exited versus the prior quarter, the largest were RVMD ($63.84M), SRZN ($38.23M), ALT ($30.40M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ANIX KORSANA BIOSCIENCES INC · $145.59M
  • VNDA VANDA PHARMACEUTICALS INC · $82.08M
  • ENTX ENTERA BIO LTD · $35.66M
  • TARS TARSUS PHARMACEUTICALS INC · $30.51M
  • VRDN VIRIDIAN THERAPEUTICS INC · $30.15M
  • AGEN AGENUS INC · $6.00M
  • RACD RESEARCH ALLIANCE CORP IV · $3.60M

Fully Exited (vs previous quarter)

  • RVMD REVOLUTION MEDICINES INC · prev qtr: $63.84M
  • SRZN SURROZEN INC · prev qtr: $38.23M
  • ALT ALTIMMUNE INC · prev qtr: $30.40M
  • FBRX FORTE BIOSCIENCES INC · prev qtr: $19.55M
  • RACC RESEARCH ALLIANCE CORP III · prev qtr: $5.35M

Insider Transactions (Form 4)

Latest TCG Crossover Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

TCG Crossover Management, LLC, based in Palo Alto, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 54 positions worth $4.16B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: PALO ALTO, CA, United States
  • SEC registration: 801-120001 (status: Approved), registered 2020-12-18
  • Regulatory AUM (Form ADV): $5.06B as of 2026-05-29
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds
  • Website: tcgcrossover.com

Portfolio Structure

  • 54 positions · $4.16B reported value (Q2 2026)
  • Top 10 holdings = 57.4% of reported value
  • Largest position: ABVX (ABIVAX SA) at 19.2%
  • Average position size: $77.05M

Sector Tilt

  • Health Care 99.3%
  • Financials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 12 new, 2 added, 9 reduced, 7 exited
  • 31 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund reduced exposure to large biotech positions (ABVX, TNGX) while adding smaller/mid-cap names (ZLAB, ANIX), suggesting a cautious view on overvalued large caps and appetite for higher-risk/reward catalysts in biotech/Health Care. 2. Key moves: - Reduced: ABVX (shares -39.0%, wt -9.0pp), TNGX (shares -25.4%, wt -2.1pp). - Added: ZLAB (shares +1.5%, wt +1.8pp), ANIX (new position, wt 4.1%). - New: ANIX (Korsana Biosciences). 3. Portfolio structure: Active, concentrated (56 positions), heavily biased toward Health Care (100% of top 10), with moderate risk appetite (mix of clinical-stage biotechs and established names). 4. Per-holding one-liner: - ABVX: Abivax SA (biopharma, unverified). - CGON: CG Oncology (cancer immunotherapy, unverified). - AMLX: Amylyx Pharmaceuticals (ALS/neuro treatments, unverified). - SYRE: Spyre Therapeutics (inflammation/autoimmunity, unverified). - TNGX: Tango Therapeutics (oncology, unverified). - ZLAB: Zai Lab (oncology/inflammation, unverified). - IMVT: Immunovant (autoimmunity, unverified). - DNTH: Dianthus Therapeutics (kidney disease, unverified). - ANIX: Korsana Biosciences (neurodegeneration, unverified). - KOD: Kodiak Sciences (eye diseases, unverified). 5. Style summary: Rotating from large-cap biotech to higher-conviction mid-caps in Health Care, with selective reductions and new bets on clinical-stage catalysts.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:08

Sector Allocation

Health Care 99.8%
Financials 0.1%
Other 0.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.66M $362.71M 10.25%
10.25%
Reduce
2 3.67M $260.18M 7.35%
7.35%
Hold
3 6.24M $181.69M 5.13%
5.13%
Hold
4 1.90M $169.21M 4.78%
4.78%
Hold
5 6.77M $168.99M 4.77%
4.77%
Reduce
6 6.23M $164.07M 4.63%
4.63%
Add
7 4.46M $150.59M 4.25%
4.25%
Hold
8 1.68M $147.63M 4.17%
4.17%
Hold
9 4.55M $145.59M 4.11%
4.11%
New
10 1.45M $137.04M 3.87%
3.87%
Hold
11 5.67M $108.24M 3.06%
3.06%
Hold
12 2.90M $102.61M 2.90%
2.90%
Hold
13 1.12M $95.65M 2.70%
2.70%
Add
14 11.02M $91.80M 2.59%
2.59%
Hold
15 1.34M $87.84M 2.48%
2.48%
Hold
16 4.12M $82.08M 2.32%
2.32%
New
17 2.50M $80.05M 2.26%
2.26%
Reduce
18 3.48M $76.02M 2.15%
2.15%
Add
19 4.62M $74.35M 2.10%
2.10%
Hold
20 3.78M $68.29M 1.93%
1.93%
Reduce
21 10.17M $63.84M 1.80%
1.80%
Add
22 12.36M $63.79M 1.80%
1.80%
Hold
23 2.06M $51.30M 1.45%
1.45%
Reduce
24 3.02M $46.25M 1.31%
1.31%
Hold
25 3.78M $45.11M 1.27%
1.27%
Reduce
26 650.00K $38.10M 1.08%
1.08%
Hold
27 12.25M $35.66M 1.01%
1.01%
New
28 1.79M $30.92M 0.87%
0.87%
Hold
29 388.16K $30.51M 0.86%
0.86%
New
30 17.75M $30.36M 0.86%
0.86%
Hold
31 2.20M $30.15M 0.85%
0.85%
New
32 947.54K $30.06M 0.85%
0.85%
Reduce
33 765.05K $29.36M 0.83%
0.83%
Reduce
34 11.11M $28.56M 0.81%
0.81%
Hold
35 1.20M $28.06M 0.79%
0.79%
Hold
36 14.50M $26.10M 0.74%
0.74%
Hold
37 7.92M $21.77M 0.61%
0.61%
Hold
38 1.82M $20.21M 0.57%
0.57%
Reduce
39 1.82M $19.88M 0.56%
0.56%
Reduce
40 10.00M $18.50M 0.52%
0.52%
Hold
41 1.26M $16.85M 0.48%
0.48%
Reduce
42 202.24K $16.11M 0.46%
0.46%
Reduce
43 11.39M $13.90M 0.39%
0.39%
Hold
44 1.06M $6.73M 0.19%
0.19%
Hold
45 406.79K $6.24M 0.18%
0.18%
Hold
46 603.89K $6.00M 0.17%
0.17%
New
47 720.32K $5.52M 0.16%
0.16%
Reduce
48 707.10K $5.47M 0.15%
0.15%
Hold
49 416.30K $4.13M 0.12%
0.12%
Hold
50 300.00K $3.60M 0.10%
0.10%
New

FAQ

What did TCG Crossover Management, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, TCG Crossover Management, LLC reported 56 equity positions worth $3.54B in aggregate; its largest disclosed positions were ABVX ($362.71M), CGON ($260.18M), AMLX ($181.69M).

How large is TCG Crossover Management, LLC's portfolio?

TCG Crossover Management, LLC reported $3.54B of long equity holdings across 56 positions as of 2026-Q3. Top-10 holdings account for 53.3% of reported value.

What is TCG Crossover Management, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/tcg-crossover-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →